Anorexigen (TNF-α, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: Their relationship with nutritional parameters

Nephrology Dialysis Transplantation

Volumn 13, Issue 6, 1998, Pages 1476-1483

  Aguilera, Abelardo ^a   Codoceo, Rosa ^a   Selgas, Rafael ^a   Garcia, Pilar ^a   Picornell, Mercedes ^a   Diaz, Candido ^a   Sanchez, Carmen ^a   Bajo, Maria Auxiliadora ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Acidosis; Cholecystokinin; Neuropeptide Y; Nutrition; Peritoneal dialysis; TNF ; Uremic anorexia

Indexed keywords

ALBUMIN; ANOREXIGENIC AGENT; APPETITE STIMULANT; CHOLECYSTOKININ; CHOLESTEROL; FIBRONECTIN; FOLIC ACID; MARKER; NEUROPEPTIDE; RETINOL BINDING PROTEIN; TRANSFERRIN; TRIACYLGLYCEROL; TRYPSIN; TUMOR NECROSIS FACTOR ALPHA; NEUROPEPTIDE Y; NITROGEN; PREALBUMIN; UREA;

ADULT; AGED; ANOREXIA; APPETITE; ARTICLE; BLOOD LEVEL; BLOOD PH; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOOD INTAKE; GLUCOSE ABSORPTION; HEMODIALYSIS PATIENT; HUMAN; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORTALITY; NAUSEA; NUTRITION; NUTRITIONAL STATUS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; VOMITING; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CROSS-SECTIONAL STUDY; RENAL CLEARANCE; UREMIA;

ADULT; AGED; AGED, 80 AND OVER; ANOREXIA; BIOLOGICAL MARKERS; CHOLECYSTOKININ; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; NUTRITION DISORDERS; NUTRITIONAL STATUS; PERITONEAL DIALYSIS; PROTEIN-ENERGY MALNUTRITION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031801970     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.6.1476     Document Type: Article

References (60)

1. Marckmann P. Nutritional status of patients on hemodialysis and peritoneal dialysis. Clin Nephrol 1988; 29: 75-78
2. Yung G, Kopple J, Lindholm B et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: a international study. Am J Kidney Dis 1991; 17: 462-471
3. Owen W, Lew N, Liu Y, Lowrie E, Lazarus J. The urea reduction ratio and serum albumin concentration as a predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329: 1001-1006
4. Teehan B, Schleifer C, Brown J, Sigler M, Raimound J. Uremic kinetic analysis and clinical outcome on CAPD: A five year longitudinal study. Adv Perit Dial 1991; 6: 181-185
5. Selgas R, Bajo MA, Fernandez-Reyes MJ, Bosque E, Lopez-Revuelta K, Jimenez J, Borrego F, De Alvaro F. An analysis of adequacy in a selected population on CAPD for over 3 years: the influence of urea and creatinine kinetics. Nephrol Dial Transplant 1993; 8: 1244-1253
6. Chertow GM, Bullard A, Lazarus JM. Nutrition and dialysis prescription. Am J Nephrol 1996; 16: 79-89
7. Blumenkrantz MJ. Nutrition. In: Daugirdas JT, Ing T, eds. Handbook of dialysis, 2nd edn. Little Brown Edit, Boston, 1995; 284-302
8. Bergstrom J. Appetite in CAPD patients. Perit Dial Int 1996; 16: S181-S184
9. Beutler B, Cerami A. Cachectin and tumor necrosis factor are two sides of the same biological coin. Nature 1986; 320: 584-588
10. Vaisman N, Hahn T. Tumor necrosis factor alpha and anorexia. Cause or effect? Metabolism 1991; 40: 720-723
11. Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson H-B, Dinarello CA, Rosenberg IA. Rheumatoid cachexia. J Clin Invest 1994; 93: 2379-2389
12. Knapp ML, Al-Sheibani-S, Riches PG, Hanham JW, Philips RH. Hormonal factors associated weight loss in patients with advanced breast cancer. Ann Clin Biochem 1991; 28: 480-486
13. Macdonald C, Rush D, Berntein K, McKenna R. Production of necrosis tumoral alpha in hemodialysis. Nephron 1993; 65: 273-277
14. Herbelin A, Nguyen AT, Zingraff J, Ureña P, Descamps-Latscha D. Influence of uremia and hemodialysis on circulating interleukin-1 and tumoral necrosis factor. Kidney Int 1990; 37: 116-125
15. Peikin SR. Role of cholecystokinin in the control of food intake. Gastroenterol Clin N Am 1989; 18: 757-775
16. Tamai H, Takemura J, Kobayashi N, Matsubayashi S, Matsukura S, Nakagawa T. Changes in plasma cholecystokinin concentration after oral glucose tolerance test in anorexia nervosa before and after therapy. Metabolism 1993; 42: 581-584
17. Chance WT, van Lammeren FM, Chen MH. Plasma and brain cholecystokinin levels in cancer anorexia. J Surg Res 1984; 36: 490-498
18. Martinez M, Hernanz A, Gomez-Cerezo J, Peña JM, Vazquez JJ, Arnalich F. Alterations in plasma and cerebrospinal fluid levels of neuropeptide in idiopathic senile anorexia. Regul Pept 1993; 49: 109-117
19. Weatherford SC, Figlewicz DP, Park CR, Wood SC. Chronic alcohol consumption increases sensibility to the anoretic effect of cholecystokinin. Am J Physiol 1993; 265 (2): R211-R215
20. Schreiber M. Can malnutrition be prevented? Perit Dial Int 1995; 15: S39-S49
21. Hosotani R, Doi R, Gu Y, Wada M, Inoue K, Fujii N, Rayford PL. Metabolism of cholecystokinin-33 in vivo: effect of L-364, 718 a CCK receptor antagonist. Ann Clin Lab Sci 1994; 24: 346-354
22. Hoffmann P, Eberlein GA, Reeve J, Bunte RH, Grandt D, Goebell H, Eysselein V. Comparison of clearance and metabolism of infused cholecystokinin 8 and 58 in dogs. Gastroenterology 1993; 105: 1732-1736
23. Owyang C, Miller LJ, Dmagno EP, Brennan LA, Go VLW. Gastrointestinal hormone profile in renal insufficiency. Mayo Clin Proc 1979; 54: 769-773
24. Stephens T, Basinski M, Bristow PK et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995; 377: 530-532
25. Saladin R, De Vos P, Guerre-Millo M, Luterque A, Girard J, Staels B, Auwerx J. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995; 377: 527-529
26. Linsay RM, Spanner E. A hypothesis: the protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients. Am J Kidney Dis 1989; 13: 382-389
27. Bergström J, Mamoun AH, Andertam B, Södersten P. Middle molecules (MM) isolated from uremic ultrafiltrate and normal urine induce dose-dependent inhibition of appetite in the rat. J Am Soc Nephrol 1994; 5: 448
28. Keshaviah PR, Nolph KD, Van Stone JC. The peak concentration hypothesis: a urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Perit Dial Int 1989; 9: 257-260
29. Fantino M, Wieteska L. Evidence for a direct central anorectic effect of tumor necrosis alpha in the rat. Physiol Behav 1993; 33: 477-483
30. Kapas L, Hong L, Cady AB, Opp MR, Postlethwaite AE, Seyer JM, Krueger JM. Somnogenic, pyrogenic, and anorectic activities of tumor necrosis factor alpha and TNF-α fragments. Am J Physiol 1993; 263: R708-R715
31. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-IB, TNF-α and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896
32. McKenna R, Macdonald C, Bernstein K, Rush T. Increased production of tumor necrosis factor activity by hemodialysis but not peritoneal dialysis patients. Nephron 1994; 67: 190-196
33. Poehlman ET, Scheffers J, Gottlieb SS, Fisher ML, Vaitekevicius P. Increased resting metabolic rate in patient with congestive heart failure. Ann Intern Med 1994; 121: 860-862
34. Paccagnella A, Calo MA, Caenaro G, Salanding V, Jus P, Simini G, Heymsfield SB. Cardiac cachexia: preoperative and postoperative management. J Parenter Nutr 1994; 18: 409-416
35. Mahony SM, Tislale MJ. Induction of weight loss and metabolic alterations by human recombinant tumoral factor necrosis. Br J Cancer 1988; 58: 345-349
36. Baud L, Fougueray B, Philippe C, Amrani A. Tumor necrosis factor and mesangial cells. Kidney Int 1992; 41: 600-603
37. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker Smith JA, Mcdonald TT. Tumor necrosis factor alpha producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-1466
38. Much SH, Walker Smith JA. Medical management of chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994; 8: 133-148
39. Noach LA, Bosma NB, Jansen J, Hoek FJ, van-Deventer SJH, Tytgat GNJ. Mucosal tumor necrosis factor-α, interleukin-1B, and interleukin-8 production in patients with helicobacter pylori infection. Scand J Gastroenterol 1994; 29: 425-429
40. Brenner D, Buck M, Feitelberg S, Chojkier M. Tumor necrosis factor alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 1990; 85: 248-255
41. Kopple JD, Chumlea WC, Gassman JJ. Relation-ship between GFR and nutritional status. Result from the MDRD study. J Am Soc Nephrol 1994; 5: 325-330
42. Lunn RL, Fishbane S, Ginsberg NS. The effect of KT/V urea on nitrogen appearance and appetite in peritoneal dialysis. Pert Dial Int 1995; 5: S50-S52
43. Chollet-Martin S, Fricker J, Apfelbaum M, Gougerot-Pocidalo MA. Tumor necrosis factor and obesity. Ann Int Med 1989; 110: 666-667
44. Walls J. Metabolic acidosis and uremia. Perit Dial Int 1995; 15:S36-S38
45. Bailey JL, Wang X, England BK, Russ Price S, Ding X, Mitch WE. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent Ubiquitin-proteasome pathway. J Clin Invest 1996; 97: 1447-1453
46. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Eng J Med 1996; 35: 1897-1905
47. Kaysen GA, Rathore V, Shearer GC, Depner TA. Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney Int 1995; 48: 510-516
48. Walsh JH. Gastrointestinal peptide hormones. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease, pathophysiology diagnosis, management, Vol. I, 4th edn. WB Saunders, Philadelphia, 1989; 78-107
49. Pirke KM, Kellner MB, Friess E, Krieg JC, Fichter MM. Satiety and cholecystokinin. Int J Eat Disord 1994; 15: 63-69
50. Hung SC, Talkad VD, Fortune KP, Jonnalagadda S, Seven C, Gianfranco DF, Gardner J. Modulation of cholecystokinin activity by albumin. Proc Natl Acad Sci USA 1995; 92: 10312-10316
51. Morley JE. Neuropeptide regulation of appetite and weight. Endocrin Rev 1987; 8: 256-287
52. Hegbrant J, Thysell H, Ekman P. Circulating neuropeptide Y in plasma from uremic patients consists of multiple peptide fragments. Peptide 1995; 16: 395-397
53. Lundberg JM, Rudehill A, Sollevi A, Hamberger B. Evidence for co-transmitter role of neuropeptide Y in the pig spleen. Br J Pharmacol 1989; 96: 675-687
54. Pernow J, Lundberg JM. Release and vasoconstrictor effects of neuropeptide Y in relation to nonadrenergic sympathetic control of renal blood flow in the pig. Acta Physiol Scand 1989; 136: 507-517
55. Marsder PA, Hall AN, Brenner BA. Reactive nitrogen and oxygen intermediates and the kidney. In: Brenner BM, Rector FC, eds. The kidney, Vol. I, WB. Saunders Company, Philadelphia, 1996; 713-753
56. Daun JM, McCarthy DO. The role of cholecystokinin in interleukin-1-induced anorexia. Physiol Behav 1993; 54: 237-241
57. Modawer LL, Andersson C, Gelin J, Lundholm KG. Regulation of food intake and hepatic protein synthesis by recombinant derivated cytokines. Am J Physiol 1988; 254: G450-G456
58. Dube MG, Xu B, Crowley WR, Kalra PS, Kalra SP. Evidence that neuropeptide Y is a physiological signal of normal food intake. Brain Res 1994; 646: 341-344
59. Davies L, Marks JL. Role of hypothalamic neuropeptide Y gene expression in body weight regulation. Am J Physiol 1994; 266: R1687-R1691
60. Valet P, Berlan M, Beauville M, Crampes F, Mota Struc JL, Lafontan M. Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin sensitive G protein. J Clin Invest 1990; 85: 291-295